US EditionExelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 ...
7 Articles
7 Articles
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Finnoexpert
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer Source link
Every year, some 16,000 cases of colorectal cancer (CCR) are diagnosed in Argentina, a disease that affects both men and women, being the second most prevalent type of cancer and also the second that causes more deaths. Despite this, specialists point out that if it is detected early the CCR can have a good prognosis, although more than half of the cases are diagnosed in the country today in a state of metastasis.Some patients with this patholog…
A new therapeutic option offers better results for patients with metastatic colon cancer, especially for those with an aggressive genetic mutation. Health article 1 Min Read 20 June, 2025 Study reveals brain abnormalities in patients who had mild or moderate COVID-19 A new research reveals that COVID may cause lasting brain alterations; know what science says and how this situation can be reversed. Ximena Ochoa Tweet WhatsApp CopyLink Copy link …
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
